EU Fast-Track Success For BioMarin’s Valrox But Not For Amarin’s Vascepa
Filings For Both Products Are Due By Year End
Just one of four accelerated assessment requests that were decided on at the European Medicines Agency this month is known to have been granted – for BioMarin’s Valrox. There was rejection for Amarin; Roche and Orchard are keeping the outcomes to themselves.
